Introduction
============

Cervical cancer (CC) is the second most common fatal gynecological malignancy worldwide.[@b1-cmar-10-4191] Despite advancements in radiotherapy and surgical therapy, numerous patients with late-stage CC still experience metastasis and recurrence, particularly in developing countries.[@b2-cmar-10-4191] Hence, efforts are being made to develop effective targeted therapies for CC.

Tumor cells undergo glycolysis even under highly oxygenated conditions, consuming a large amounts of glucose and generating lactate, a phenomenon termed aerobic glycolysis or the Warburg effect.[@b3-cmar-10-4191] Pyruvate kinase isozyme type M2 (PKM2) is an isozyme of pyruvate kinase that functions as a rate-limiting enzyme catalyzing the conversion of phosphoenolpyruvate and adenosine diphosphate to pyruvate in the final step of the glycolytic pathway.[@b4-cmar-10-4191] PKM2 is overexpressed in several malignancies, including CC and is associated with tumor development and poor prognosis.[@b5-cmar-10-4191],[@b6-cmar-10-4191] Landt et al[@b7-cmar-10-4191] reported that PKM2 can be used as a biomarker for differentiating between malignant and premalignant cervical lesions. Furthermore, a study showed that positive PKM2 expression indicated the development of cervical carcinoma.[@b8-cmar-10-4191] However, the function of PKM2 in the tumorigenesis and progression of CC is yet to be explored in detail.

The epithelial--mesenchymal transition (EMT) is a biological process through which epithelial cells lose their polarity and become mesenchymal cells, gaining migratory properties that increase invasiveness in cancer progression.[@b9-cmar-10-4191],[@b10-cmar-10-4191] Growing evidence suggests that the EMT is associated with metastasis and occurs during the development of various carcinomas, including CC.[@b11-cmar-10-4191] Numerous signaling pathways are involved in the EMT process, including the Wnt, Notch, nuclear factor-kappa B, TGF-β, and RTK/Ras.[@b12-cmar-10-4191] Among them, Wnt/β-catenin is essential for the regulation of cell growth and development; its abnormal activation is common in human cancers, including CC.[@b13-cmar-10-4191] In the Wnt pathway, inactivation of a destruction complex targeting β-catenin for proteasomal degradation results in the translocation of β-catenin to the nucleus, which activates the downstream target oncogenes of β-catenin, such as c-Myc and cyclin D1.

To determine the expression pattern of PKM2 in CC, we profiled the expression status of PKM2 in CC tissues. Moreover, we analyzed the association between the expression of PKM2 and the clinicopathological characteristics of CC. After examining the mechanisms underlying the association between PKM2 and metastasis, we found that Wnt/β-catenin signaling was involved in PKM2-mediated invasion.

Materials and methods
=====================

Tissue samples
--------------

Between June 2016 and December 2017, a total of 103 cervical squamous cell carcinoma (SCC) specimens were collected through biopsy from patients who were not subjected to preoperative radiotherapy or chemotherapy at Sun Yat-sen University Cancer Center. Fifteen normal cervical epithelial tissue samples were obtained from patients without CC through surgical resection at the same center. A total of 36 paired CC tissues and adjacent nontumor tissues were randomly selected for quantitative polymerase chain reaction (qPCR), and seven paired tissues were selected for Western blot analysis. All CC and normal tissues were confirmed by pathological diagnosis. The clinicopathological information collected included age, tumor size, differentiation grade, lymph node metastasis, and International Federation of Gynecology and Obstetrics (FIGO) stage. All patients provided written informed consent, and the study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center.

Immunohistochemistry
--------------------

Immunohistochemical analysis was performed to measure PKM2 protein expression. In brief, samples were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and processed for immunohistochemical staining. Slides were baked at 60°C for 1 hour, followed by deparaffinization with xylene and rehydration. Subsequently, they were treated with 3% hydrogen peroxide to quench the endogenous peroxidase activity, followed by incubation with 5% bovine serum albumin to block nonspecific binding. Sections were incubated with anti-PKM2 (1:150 dilution, cell-signalling technology \[CST\]) overnight at 4°C. After washing, the tissue sections were treated with a secondary antibody, followed by incubation with conjugated rabbit peroxidase streptavidin. Color was developed using a DAB (3,3′-diaminobenzidine) Horseradish Peroxidase Color Development Kit (Fuzhou Maixin Biotech Inc., Fuzhou, China). Subsequently, the tissue sections were then counterstained with hematoxylin, dehydrated, and mounted. Finally, the sections were viewed under a bright-field microscope. The tissue sections subjected to immunohistochemical staining for PKM2 were reviewed and scored separately by two pathologists blinded to clinical parameters. Any disagreements were arbitrated by a third pathologist. To assess PKM2 expression, staining intensity was scored as negative =0; weak =1; moderate =2; and strong =3, and staining extent was scored as 1%--25%=1; 26%--50%%=2; 51%--75%%=3; and \>76%=4. The final score was calculated by multiplying these two variables. If the total score was \>7, it was defined as high expression, or if not, it was defined as low expression.

Cell culture
------------

The normal cervical epithelial ECT cell line and the human CC cell lines HeLa, SiHa, Caski, MS751, HeLa229, and C33A were obtained from American Type Culture Collection (Manassas, VA, USA). SiHa, MS751, and HeLa229 cells were cultured in DMEM (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) and penicillin--streptomycin, whereas other cell lines were cultured in Roswell Park Memorial Institute-1640 medium containing 10% FBS at 37°C in a humidified tissue culture incubator under 5% CO~2~.

Real-time (RT) qPCR
-------------------

Total RNA from cells or tissues was extracted using TRI reagent (TRIzol, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol, and 500 ng of RNA was used to obtain cDNA through reverse-transcription by using PrimeScript RTMasterMix (Takara Bio, Kusatsu, Japan). A quantitative RT (qRT)-PCR reaction was conducted using a SYBR Green PCR Master Mix (Takara Bio) on a CFX96 Real-Time PCR Detection System (Bio-Rad, Hercu-les, CA, USA). Primers used in this study are listed in [Table S1](#SD4-cmar-10-4191){ref-type="supplementary-material"}. Relative expression was determined by normalizing to the expression of β-actin. Relative gene expression levels were detected and calculated using the ΔΔCt comparative method.

Western blot assay
------------------

Total proteins were extracted as previously described.[@b14-cmar-10-4191] Tissues and cells were lysed in RIPA buffer (Beyotime, China), and protein concentrations were measured using the bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA). Equal protein extracts were run on SDS-PAGE and subsequently transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA). After the membrane was blocked for 1 hour using 5% skim milk, it was incubated with a primary antibody overnight at 4°C. Finally, the membrane was incubated with their respective horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 2 hours. The sources of the antibodies and their concentrations are as follows: rabbit anti-PKM2 (1:1000, CST), rabbit anti-c-Myc (1:1000, CST), mouse anti-E-cadherin (1:1000, BD), mouse anti-vimentin (1:1000, BD), mouse anti-β-catenin (1:1000, Santa Cruz Biotechnology Inc.), rabbit anti-slug (1:1000, CST), rabbit anti-snail (1:1000, CST), rabbit anti-cycline D1 (1:1000, CST), and rabbit anti-glyceraldehyde-3-phosphate dehydrogenase (1:1000, CST). The protein bands of interest were visualized using enhanced chemiluminescence reagents (Millipore, Burlington, MA, USA).

Generation of stable PKM2 knockdown or overexpression cells
-----------------------------------------------------------

Enhanced green fluorescent protein-tagged shRNA against PKM2 (shPKM2) and PKM2-overexpression lentivirus were purchased from Shanghai Genechem Co., Ltd; the sequences are shown in [Table S2](#SD5-cmar-10-4191){ref-type="supplementary-material"}. In brief, cells were grown to 50%--60% confluence and infected with lentivirus according to the manufacturer's instructions. After 12 hours infection, the virus-containing medium was removed, and stable clones were selected with 8 µg/mL of puromycin for 48 hours.

Colony formation assay
----------------------

For colony formation, the indicated cells were plated at 200 cells/well and incubated for 14 days to form colonies. The colonies were fixed using methanol and stained with 0.5% crystal violet for 15 minutes; and colonies of \>50 cells were counted under a light microscope.

Transwell assay
---------------

Migration and invasion were assessed using Transwell plates. For the invasion assay, Matrigel chambers (BD Biosciences, San Jose, CA, USA) were used to determine the effect of cells on invasion according to the manufacturer's instructions. The indicated cells at a density of 5×10^4^ cells/well were resuspended in 200 µL into the upper chamber (8-µm pore size, Costar, Corning, NY, USA) of a Transwell system, whereas the lower chamber was filled with 0.5 mL of medium supplemented with 10% FBS. After incubation for 24 hours at 37°C, the invasive cells were fixed with 100% methanol and stained with 0.5% crystal violet before counting under an inverted microscope. For the migration assay, the indicated cells were plated on uncoated Matrigel upper chambers. The transmembraned cells were estimated under a microscope (Nikon, Tokyo, Japan) at 200× magnification.

Cell Counting Kit-8 (CCK-8) assay
---------------------------------

The indicated cells were seeded into 96-well plates at density of 3×10^3^ cells per well. Cell viability was determined using CCK-8 (Dojindo, Kumamoto, Japan) every 24 hours and by measuring absorbance at 450 nm using an ELx800 plate reader (BioTek, Winooski, VT, USA) following the manufacturer's instructions.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 18.0 (SPSS Inc, Chicago, IL, USA). Data are presented as the mean ± SD. The chi-squared test was used to analyze clinicopathological characteristics. Comparisons between two groups were evaluated using Student's *t*-test. Differences among the groups were tested using a one-way ANOVA. All experiments were repeated at least three times. A *P* value of\<0.05 was considered statistically significant.

Results
=======

Expression of PKM2 is significantly upregulated in CC
-----------------------------------------------------

To evaluate the expression status of PKM2 in human CC tissues, the mRNA expression level of PKM2 of 36-paired CC and adjacent noncancerous tissues were examined through qRT-PCR. The mRNA expression level of PKM2 was upregulated in CC tissues than in adjacent noncancerous ones ([Figure 1A](#f1-cmar-10-4191){ref-type="fig"}; P\<0.001). We also found that the PKM2 protein level expression was higher in CC tissues than in adjacent noncancerous ones ([Figure 1B](#f1-cmar-10-4191){ref-type="fig"}). Accordingly, PKM2 expression was further examined in six CC cell lines and one normal epithelial cell line through qRT-PCR and Western blot. The results revealed that PKM2 expression was considerably higher in CC cell lines than in normal epithelial cell line ([Figure 1C, D](#f1-cmar-10-4191){ref-type="fig"}). These results indicated that both mRNA and protein levels of PKM2 were significantly increased in CC.

Correlations between PKM2 expression and clinicopathological parameters in CC
-----------------------------------------------------------------------------

To determine the clinical significance of PKM2 in the development and progression of CC, an immunohistochemical assay was performed. Representative photographs of PKM2 expression are shown in [Figure 2](#f2-cmar-10-4191){ref-type="fig"}, where the expression of PKM2 can be observed to exhibit strong staining in cervical SCC and was predominantly localized in the cytoplasm, whereas the expression of PKM2 in normal cervical epithelial tissues were negative, indicating that PKM2 was upregulated in CC. The relationships between PKM2 expression and the clinicopathological factors of CC patients are shown in [Table 1](#t1-cmar-10-4191){ref-type="table"}. Our results demonstrated that PKM2 expression was positively correlated with the FIGO stage (*P*=0.001) and lymph node metastasis (*P*=0.023). However, no significant difference existed between PKM2 expression and tumor size, differentiation, and age. Furthermore, we evaluated the prognostic effect of PKM2 expression by using Kaplan--Meier Plotter analysis in the publicly available web-based tool GEPIA (<http://gepia.cancer-pku.cn/>) based on the TCGA and GTEx databases. The Kaplan--Meier plots of overall survival (OS; [Figure S1](#SD1-cmar-10-4191){ref-type="supplementary-material"}) indicated that patients with high expression of PKM2 mRNA were associated with lower OS (*P*=0.015), whereas no significant difference existed in disease-free survival in CC (*P*=0.74). These data indicate that PKM2 is associated with the progression and poor prognosis of CC.

Effect of PKM2 on the cell proliferation of CC in vitro
-------------------------------------------------------

To investigate the biological roles of PKM2 in CC progression, HeLa and SiHa cells were transfected with lentivirus shRNA vectors containing nontargeting shRNA (Control) or shRNA against PKM2 as models to generate stable cell lines. Western blotting and qPCR analysis showed that the PKM2 knockdown dramatically reduced PKM2 expression compared with the Control group ([Figure 3A, B](#f3-cmar-10-4191){ref-type="fig"}, [Figure S2](#SD2-cmar-10-4191){ref-type="supplementary-material"}). Next, we examined the cell proliferative capacity of PKM2 on CC cells by using CCK-8 and colony formation assays. As shown in [Figure 3C--F](#f3-cmar-10-4191){ref-type="fig"} results indicated that the suppression of PKM2 significantly inhibited cell proliferation and reduced cell viability compared with the Control group in both cell lines (P\<0.01 and P\<0.05). To further confirm the role of PKM2 in cell proliferation, we selected the MS751 and C33A cell lines with low PKM2 expression to construct the PKM2 overexpression model (LV-PKM2) and evaluated their cell viability. PKM2 was successfully overexpressed in both the cell lines ([Figure S3A, B](#SD3-cmar-10-4191){ref-type="supplementary-material"}), and the CCK8 assay showed that the overexpression of PKM2 significantly enhanced cell proliferation ([Figure S3C](#SD1-cmar-10-4191){ref-type="supplementary-material"}). Collectively, our data implied that PKM2 affected proliferation in CC cells.

Knockdown of PKM2 suppresses CC migration and invasion in vitro
---------------------------------------------------------------

CC is characterized by a high metastasis potential in clinical practice. Subsequently, we determined whether PKM2 affects the cell migratory and invasive capacities of CC cells. The results of the transwell assay showed that knockdown of PKM2 markedly reduced the migration and invasion ability of HeLa and SiHa cells. Representative images and quantitative graphs representing the cell count are shown in [Figure 4](#f4-cmar-10-4191){ref-type="fig"}. However, this result was in opposition to that of C33A and MS751 cells between the overexpression and Control groups ([Figure S3D, E](#SD3-cmar-10-4191){ref-type="supplementary-material"}). The results suggested that PKM2 plays a significant role in cell migration and invasion in CC cells.

PKM2 regulates the expression of EMT markers through Wnt/β-catenin signaling
----------------------------------------------------------------------------

EMT is associated with CC.[@b15-cmar-10-4191] To investigate the effect of PKM2 on EMT in CC, we examined the expression of classic epithelial (E-cadherin) and mesenchymal (vimentin, Snail, and Slug) markers after PKM2 downregulation in CC cells. As shown in [Figure 5A, B](#f5-cmar-10-4191){ref-type="fig"}, decreased levels of the mesen-chymal markers vimentin, Snail, and Slug were observed in the PKM2-knockdown CC cells, while the epithelial marker E-cadherin was significantly upregulated in SiHa cells, and barely detected in HeLa cells. However, the expression of E-cad was downregulated and those of the EMT markers vimentin, Snail, and Slug were upregulated in the PKM2 over-expression group of both cell lines. These results demonstrated that PKM2 knockdown potentially inhibited EMT in CC cells.

The Wnt/β-catenin pathway plays a crucial role in cell proliferation and promotes EMT in cancer development. To examine whether PKM2 regulates the activity of the Wnt/β-catenin pathway, we examined the related protein expression level. Compared with the Control group, knockdown of PKM2 significantly reduced β-catenin, c-Myc, and cyclin D1 expression levels in both cell lines. PKM2 overexpression in MS751 and C33A cells led to an opposite effect. Collectively, these data indicate that Wnt/β-catenin signaling has a crucial role in PKM2-induced CC cell migration and invasion.

Discussion
==========

PKM2 is upregulated and acts as a tumor promotor in various human cancers.[@b10-cmar-10-4191],[@b16-cmar-10-4191] Consistently, in the current study, we investigated the role of PKM2 in CC and determined the underlying mechanism. We found that PKM2 expression was remarkably increased in CC tissues and cell lines. Furthermore, we verified that PKM2 facilitated the EMT process through the Wnt/β-catenin pathway to promote cell proliferation and invasion in CC. Therefore, our data suggest that PKM2 may be a novel biomarker for CC therapy.

Aerobic glycolysis is widely accepted as a hallmark of invasive cancers; thus, regulation of aerobic glycolysis has become a popular research topic in recent years.[@b17-cmar-10-4191] PKM2 is one of the four isozymes of PK (M1, M2, L, and R) that is mainly expressed in embryonic tissues and proliferative cells, especially in cancer cells.[@b18-cmar-10-4191] PKM2 is a step-limiting member of the glycolytic pathway, and emerging evidence indicates that PKM2 is closely associated with the onset and development of multiple tumors. For example, aberrant expression of PKM2 in esophageal SCC,[@b19-cmar-10-4191] hepatocellular carcinoma,[@b20-cmar-10-4191] and colorectal cancer[@b21-cmar-10-4191] has been associated with aggressive disease, poor differentiation, metastases development, and poor clinical prognosis. Nevertheless, few studies have explored the function of PKM2 in detail in the onset and development of CC. In this study, we determined the expression of PKM2 in human CC tissues and investigated its possible roles. Specifically, PKM2 expression was significantly increased in CC tissues, and the strong positive staining in CC tissue samples further supported the results. Additionally, PKM2 upregulation was positively correlated with the FIGO stage and lymph node metastasis, suggesting that PKM2 plays a crucial role in CC development. In addition, the publicly available web-based tool GEPIA showed that high PKM2 expression predicted poor outcomes, which implied that PKM2 may serve as an independent prognostic indicator of CC.

To further explore the biological effect of PKM2 on CC cells, we investigated the effect of PKM2 knockdown on the proliferation, invasion, and migration of two CC cell lines. First, we examined the expression level of PKM2 in different CC cell lines. Our results showed that PKM2 expression was upregulated in CC cell lines. We selected HeLa and SiHa cell lines transfected with shRNA of PKM2, which indicated high PKM2 expression as the cell model. The findings of in vitro experiments showed that the knockdown of PKM2 inhibited CC cell proliferation, migration, and invasion. By contrast, the overexpression of PKM2 promoted cell proliferation and invasion, which was consistent with the results of a previous study.[@b22-cmar-10-4191]

Although the role of PKM2 in cell migration and invasion has been described extensively, its mechanisms remain unclear. EMT is a biological process through which epithelial cells lose their polarity, which promotes the malignancy in tumor progression. Loss of E-cadherin and acquisition of vimentin are two critical steps in EMT.[@b23-cmar-10-4191] The members of the Snail family, Snail and Slug, play a critical role in EMT during embryonic development and tumor progression. Emerging research has suggested that PKM2 plays a role in tumorigenesis through EMT. One study reported that PKM2 functions as an interacting partner of epidermal growth factor receptor (EGFR) and induces the EMT phenotype in colon cancer.[@b24-cmar-10-4191] Furthermore, STAT3 activation is closely related to PKM2. Yang et al[@b25-cmar-10-4191] reported that overexpression of PKM2 promoted colorectal cancer cell migration and cell adhesion by inducing EMT through the STAT3 signaling pathway. In the current study, we analyzed the expression patterns of relevant genes involved in EMT, including E-cadherin, vimentin, Snail, and Slug. The transcription factors Snail and Slug were significantly repressed after knockdown of PKM2 in HeLa and SiHa cells, whereas the epithelial marker E-cadherin was upregulated. By contrast, overexpression of PKM2 promoted EMT, indicating that PKM2 plays a crucial role in EMT in CC. These data suggest that PKM2 knockdown suppressed tumor metastasis by preventing the EMT process in CC cells.

Abnormal activation of the Wnt/β-catenin signaling pathway plays a crucial role in PKM2-related proliferation and invasion. Yang et al[@b26-cmar-10-4191] demonstrated that EGFR activation induces K433 of PKM2 to bind to c-Src-phosphorylated Y333 of β-catenin, leading to histone H3 acetylation and cyclin D1 expression and further promoting tumor cell proliferation and brain tumor development. Furthermore, Wu et al[@b27-cmar-10-4191] found that PKM2 depletion provokes glutamine metabolism by enhancing the β-catenin signaling pathway, thereby activating its downstream c-Myc-mediated glutamine metabolism in colon cancer. Another study found that CCs overexpressed β-catenin through DNA methylation of the promoter region.[@b28-cmar-10-4191] One study showed that PKM2 affected the β-catenin signaling pathway through miR-200a.[@b29-cmar-10-4191] These studies indicate that PKM2 is concerned with the regulation of the Wnt/β-catenin signaling pathway. Nuclear β-catenin is believed to be the hallmark of activation of the canonical Wnt pathway. We further examined the expression of two β-catenin downstream genes, c-Myc and cyclin D1, to clarify the effects of PKM2 expression on the Wnt pathway in CC. We found that PKM2 suppression significantly reduced the β-catenin level, and c-Myc and cyclin D1 levels in vitro, whereas PKM2 overexpression increased cyclinD-1 and c-Myc levels as well as β-catenin expression, indicating that PKM2 may participate in regulating the Wnt pathway in CC. These data suggest that knockdown of PKM2 inhibited the proliferation and invasion of human CC cells in part through suppressing Wnt/β-catenin signaling pathway activation. However, more research is required to clarify the role of Wnt/β-catenin in PKM2-related proliferation and invasion in CC.

Overall, our study confirmed the positive expression of PKM2 in human CC tissues and cell lines, as well as demonstrated that PKM2 promotes CC cell migration and invasion by inducing EMT through the Wnt/β-catenin signaling pathway. However, future studies should collect a large sample size of CC tissues and analyze the relationship between PKM2 expression and the prognosis of CC patients. A more comprehensive investigation will be conducted in vivo.

Supplementary materials
=======================

###### 

PKM2 high expression is associated with poor survival in CC.

**Notes:** Kaplan--Meier plots were generated using the web-based tool GEPIA (<http://gepia.cancer-pku.cn/>). The results revealed an association between high expression of PKM2 and unfavorable overall survival (**A**) and disease-free survival (**B**) in patients with CC.

**Abbreviations:** CC, cervical cancer; PKM2, pyruvate kinase isozyme type M2.

###### 

Transfection efficiency in SiHa and HeLa cells.

**Notes:** Stable PKM2 knockdown cells were screened after incubation with 8 μg/mL of puromycin for 48 hours. Green fluorescence protein was detected using a Nikon Eclipse fluorescent microscope.

**Abbreviation:** PKM2, pyruvate kinase isozyme type M2.

###### 

Effects of PKM2 overexpression on cell proliferation, migration, and invasion.

**Notes:** PKM2 expression in two cell lines was analyzed using qRT-PCR (**A**) and Western blot (**B**). (**C**) The cell proliferative capacity was detected using CCK-8 assay. PKM2 overexpression promoted MS751 and C33A cell proliferation. (**D**, **E**) The migratory and invasive potentials in the PKM2 overexpression MS751 and C33A cells were evaluated using the transwell assay with or without Matrigel; representative pictures are shown. PKM2 overexpression promoted MS751 and C33A cell migration and invasion. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.

**Abbreviations:** CCK-8 Cell Counting Kit-8; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; OD, optical density PKM2, pyruvate kinase isozyme type M2; qRT-PCR, quantitative real-time polymerase chain reaction.

###### 

The primers used in qRT-PCR analysis

  Gene      Sense and antisense primer (5′-3′)
  --------- ---------------------------------------------
  β-actin   CTCCATCCTGGCCTCGCTGT GCTGTCACCTTCACCGTTCC
  PKM2      ATGTCGAAGCCCCATAGTGAA TGGGTGGTGAATCAATGTCCA

**Abbreviation:** PKM2, pyruvate kinase isozyme type M2; qRT-PCR, quantitative real-time polymerase chain reaction; shPKM2, shRNA against PKM2.

###### 

Sequences for shRNAs

  shRNA     Target sequences (5¢--3¢)
  --------- ---------------------------
  Control   TTCTCCGAACGTGTCACGT
  shPKM2    CCATAATCGTCCTCACCAA

**Abbreviations:** PKM2, pyruvate kinase isozyme type M2; shPKM2, shRNA against PKM2.
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![PKM2 expression is increased in CC.\
**Notes:** (**A**) Significant upregulation of PKM2 mRNA expression level was observed in CC tissues compared with paired adjacent nontumor ones; β-actin was used as the loading control. (**B**) Western blot was conducted to examine the expression levels of PKM2 in seven CC tissue specimens and their matched adjacent nontumor ones; PKM2 expression was significantly higher in the seven tumor tissues than in the matched paracancerous controls. N: adjacent nontumor tissues; T: CC tissue. (**C**) PKM2 mRNA in cervical cell lines was detected using qRT-PCR and relative quantification analysis was normalized to β-actin mRNA. (**D**) PKM2 protein expression was analyzed in CC cell lines using Western blot. \*\*\**P*\<0.001.\
**Abbreviations:** CC, cervical cancer; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PKM2, pyruvate kinase isozyme type M2; qRT-PCR, quantitative real-time polymerase chain reaction.](cmar-10-4191Fig1){#f1-cmar-10-4191}

![Immunostaining of PKM2 in normal cervical epithelial tissue and CC tissues.\
**Notes:** (**A**) Negative expression of PKM2 in normal cervical epithelial tissues. (**B**) Weak expression, (**C**) moderate expression, (**D**) strong expression of PKM2 in CC tissues, and (**E, F**) the relationships between PKM2 expression and the clinicopathologically significant aspects of CC.\
**Abbreviations:** CC, cervical cancer; PKM2, pyruvate kinase isozyme type M2.](cmar-10-4191Fig2){#f2-cmar-10-4191}

![Knockdown of PKM2 inhibited proliferation in CC cells.\
**Notes:** (**A, B**) PKM2 knockdown efficiency was confirmed by Western blot and qRT-PCR in HeLa and SiHa cells. (**C, D**) The effects of PKM2 knockdown on proliferation were evaluated using CCK-8 assay. (**E, F**) The effects of PKM2 knockdown on colony formation were determined using colony formation assay. The results shown are the mean ± SD (\**P*\<0.05, \*\**P*\<0.01) of three independent experiments.\
**Abbreviations:** CC, cervical cancer; PKM2, pyruvate kinase isozyme type M2; qRT-PCR, quantitative real-time polymerase chain reaction.](cmar-10-4191Fig3){#f3-cmar-10-4191}

![Knockdown of PKM2 inhibited cell invasion and migration of SiHa and HeLa cells in vitro.\
**Notes:** (**A, C**) The migratory potentials and invasion in HeLa and SiHa cells after PKM2 knockdown were evaluated by Transwell assays; representative pictures are shown. (**B, D**) Numbers of migrating and invading cells were analyzed after knockdown of PKM2. \*\**P*\<0.01, \*\*\**P*\<0.001.\
**Abbreviation:** PKM2, pyruvate kinase isozyme type M2; shPKM2, shRNA against PKM2.](cmar-10-4191Fig4){#f4-cmar-10-4191}

![Effect of PKM2 on EMT and the Wnt signaling pathway.\
**Notes:** (**A**) The effect of PKM2 knockdown on the expression of E-cadherin, vimentin, Snail, and Slug were assessed by Western blot in HeLa and SiHa cells. β-catenin and downstream target genes c-Myc and cyclin D1 were assessed by Western blot after knockdown of PKM2. (**B**) The effects of PKM2 upregulation on protein levels of E-cadherin, vimentin, Snail, Slug, β-catenin, c-Myc, and cyclin D1; GAPDH level was used as a loading control.\
**Abbreviations:** EMT, epithelial--mesenchymal transition; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PKM2, pyruvate kinase isozyme type M2; shPKM2, shRNA against PKM2.](cmar-10-4191Fig5){#f5-cmar-10-4191}

###### 

Correlation between PKM2 expression and clinicopathological parameters for cervical carcinoma

  Characteristics               Patients (n=103)   PKM2 expression   *P*-value   
  ----------------------------- ------------------ ----------------- ----------- ------------------------------------------------------
                                                                                 
  **Age (years)**                                                                
  \<55                          49                 25                24          0.771
  ≥55                           54                 26                28          
  **Stage**                                                                      
  I + II                        55                 36                19          0.001[\*\*](#tfn2-cmar-10-4191){ref-type="table-fn"}
  III + IV                      48                 15                33          
  **Histopathological grade**                                                    
  Moderate + Poor               44                 23                21          0.629
  Well                          59                 28                31          
  **Size (cm)**                                                                  
  \<4.0                         38                 21                17          0.372
  ≥4.0                          65                 30                35          
  **Lymph node**                                                                 
  (−)                           51                 31                20          0.023[\*](#tfn1-cmar-10-4191){ref-type="table-fn"}
  (+)                           52                 20                32          

**Note:**

*P*\<0.05,

*P*\<0.01.

**Abbreviation:** PKM2, pyruvate kinase isozyme type M2.
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